ENDOCEUTICS

Active

Public limited companyfounded 2018active for 7 yearsBelliardstraat 40, 1040 Brussel, Belgium137 active companies are registered at this addressKBO/BCE: BE 0715.565.040

Summary

ENDOCEUTICS has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €234,743 and a net result of €348,842. Equity is growing by about 27% per year across the filed financial years. Its solvency ranks better than 11% of 6,142 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).

Risk analysisFollow Report Compare

ENDOCEUTICSActiveChecked score 70/100

Risk analysis Report Compare

Activity

Wholesale of pharmaceutical and medical goods

NACE 46460

Size

€3.5mtotal assets 2025

Equity: €234,743
Profit: €348,842

Financial health

70 Healthy Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.6%

Structure

Parent: Myriel Pharmaceuticals LLC.

Muriel Pharmaceuticals ULCDirector · permanent representative Apurva Saraf
Myriel Pharmaceuticals LLCDirector · permanent representative Serge Ilin-Schneider

2025 accounts filed 60 days late2 of 5 deeds summarised

Why 70raises riskLast filed accounts filed 60 days late; 1 of the last 3 lateEquity €234,743 (6.8% of total assets)lowers riskSize: total assets €3.5mFigures for financial year 2025 (filed 30-09-2026)Show the evidence

Checked score

Score 2025

70 / 100

Healthy

Probability in this band: 0.55% to 1.5%

Financially better than 44% of its sector peers (NACE 46, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 32+9

equity 6.8% of total assets

Liquidity 22+11

short-term debt 93.1% · cash 17.7%

Profitability 63+19

return on assets 10.1%

Bankruptcy probability, 12 months

0.6% Low

0%0.5%1.5%4%10%≥ 25%

About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,375 companies, NACE 46, small)

Last 24 months 11-2024: 1.1% 12-2024: 1.1%● unchanged vs 11-2024 01-2025: 1.1%● unchanged vs 12-2024 02-2025: 1.2%▲ +0.1 percentage points vs 01-2025 03-2025: 1.1%▼ -0.1 percentage points vs 02-2025 04-2025: 1.1%● unchanged vs 03-2025 05-2025: 1.2%▲ +0.1 percentage points vs 04-2025 06-2025: 1.3%▲ +0.1 percentage points vs 05-2025 07-2025: 1.5%▲ +0.2 percentage points vs 06-2025 08-2025: 2.3%▲ +0.8 percentage points vs 07-2025highest value 09-2025: 0.3%▼ -2.0 percentage points vs 08-2025lowest value 10-2025: 0.3%● unchanged vs 09-2025 11-2025: 0.3%● unchanged vs 10-2025 12-2025: 0.3%● unchanged vs 11-2025 01-2026: 0.3%● unchanged vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.3%● unchanged vs 02-2026 04-2026: 0.4%▲ +0.1 percentage points vs 03-2026 05-2026: 0.4%● unchanged vs 04-2026 06-2026: 0.6%▲ +0.2 percentage points vs 05-2026 07-2026: 0.6%● unchanged vs 06-2026 08-2026: 1.0%▲ +0.4 percentage points vs 07-2026 09-2026: 1.1%▲ +0.1 percentage points vs 08-2026 10-2026: 0.6%▼ -0.5 percentage points vs 09-2026

Credit of up to €16,000 on 30-day terms is acceptable

Liquidity tight (current ratio 1.07, compared with 0.98 in 2024, below the usual 1.5; short-term debt: 93.1% and cash: 17.7% of total assets), and 93.2% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 10% on solvency, 19% on liquidity, 49% on profitability and 99% on growth.

The bankruptcy probability was computed on 27-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises risk

Size: total assets €3.5m

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Last filed accounts filed 60 days late; 1 of the last 3 late

NBB · filings

Figures for financial year 2025 (filed 30-09-2026)

NBB · annual accounts

Equity €234,743 (6.8% of total assets)

NBB · annual accounts

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 11% of 6142 sector peers (2025).

NBB · sector comparison

Position among 6142 sector peers

Solvency

better than 11%

← weakest strongest →

2025 accounts filed 60 days late

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-09-2026, 60 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.

NBB · 7 filings

Deviation from the deadline

2025

60 days late

2024

14 days late

2023

13 days early

2022

90 days early

2021

8 days late

2020

2 days early

2019

36 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 8 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 August (4 of the last 5 filed years within 52 days of that day).

Companies Code · seven months

Where today falls in the filing period

28-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

29-09-2026 Annual accounts filedfinancial year 2025 · full…
31-12-2025 Highest result from 2019 to 2025net €348,842 ▲192%
31-12-2025 Equity above €200,000equity €234,743

Key points

Positive: Result rose in 2025from €119,480 to €348,842 ▲ 192% View
Caution: Among the weakest 11% on solvencysector median 45.2% · 6,142 companies 6.8% View
Controlled by Myriel Pharmaceuticals LLC.known shareholders 100% parent View

By topic

Financials

Financial year: 2025
Total assets: €3.5m
Profit: €348,842
Solvency: 6.8%

Total assets▼ 26.6%

Net result

20192025

Go to Financials

Board & ownership

Board: 2 members
Parent: Myriel Pharmaceuticals LLC.
Known shareholders: 100%

Muriel Pharmaceuticals ULCDirector
Myriel Pharmaceuticals LLCDirector

Go to Board & ownership

Timeline

Events: 13
Since: 2020
Next accounts: by 31-07-2027

14-08-2025Annual accounts filed
18-07-2024Annual accounts filed
22-02-2024Resignations: ENDOCEUTICS INC. (director) and ENDOCEUTICS PHARMA…

Go to Timeline

Company details

Legal form: Public limited company
Activity: Wholesale of pharmaceutical and medical goodsNACE 46460
Founded: 06-12-2018
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 8

Annual meeting: First Monday of June at 15:00
Purpose: “Le dépôt des demandes pour,acquérir et détenir,gérer,activer,donner en licence et…” (deed in French)

Go to Articles of association

Key facts about ENDOCEUTICS

What is the company number of ENDOCEUTICS?: 0715.565.040. In Belgium the VAT number is the company number with BE in front: BE 0715.565.040.
Where is ENDOCEUTICS based?: The registered office is at Belliardstraat 40, 1040 Brussel.Company details
What does ENDOCEUTICS do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of ENDOCEUTICS?: Public limited company (NV).
When was ENDOCEUTICS founded?: On 06-12-2018.
Is ENDOCEUTICS still active?: Yes, ENDOCEUTICS is an active enterprise in the KBO register.
What is the turnover of ENDOCEUTICS?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is ENDOCEUTICS profitable?: In financial year 2025, ENDOCEUTICS made a profit of €348,842.
Where can I find the annual accounts of ENDOCEUTICS?: ENDOCEUTICS filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ENDOCEUTICS due?: By 31-07-2027, for financial year 2026.Timeline